基线英夫利西单抗清除率与急性重症溃疡性结肠炎结肠切除需求相关
本研究纳入39例住院启动英夫利西单抗治疗的急性重症溃疡性结肠炎(ASUC)患者,计算基线英夫利西单抗清除率,比较6个月时需结肠切除与未切除患者的清除率差异。多变量分析中基线清除率是唯一与结肠切除相关的因素。
要点
- ASUC患者基线英夫利西单抗清除率越高,6个月内结肠切除风险越高。
- 清除率阈值0.627 L/d识别结肠切除的敏感性80.0%、特异性82.8%(AUC 0.80)。
- 清除率≥0.627 L/d者6个月结肠切除率61.5%,低于该值者仅7.7%。
核心结论
- 住院ASUC患者启动英夫利西单抗前计算的基线清除率越高,结肠切除率越高。
- 基线英夫利西单抗清除率是多变量分析中唯一与结肠切除相关的因素。
- 30天和1年结果与6个月结果相似。
研究设计与样本
- 研究纳入39例住院并启动英夫利西单抗治疗的ASUC患者。
- 基于现有公式计算基线英夫利西单抗药物清除率。
- 主要比较6个月时需结肠切除与未切除患者的清除率差异。
主要发现
- 清除率阈值0.627 L/d识别结肠切除的敏感性80.0%、特异性82.8%,AUC 0.80。
- 需结肠切除者住院期间英夫利西单抗剂量更高。
关键数值与推荐
- 基线英夫利西单抗清除率阈值0.627 L/d:敏感性80.0%、特异性82.8%、AUC 0.80。
临床怎么用
- 基线英夫利西单抗清除率或可用于识别ASUC患者结肠切除高风险。
- 目前缺乏英夫利西单抗浓度数据,需药代动力学模型指导ASUC患者剂量比较试验。
局限性
- 研究样本量较小(39例)。
- 缺乏英夫利西单抗浓度数据。
- 需开发ASUC患者英夫利西单抗药代动力学模型以开展清除率指导与标准剂量比较试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hospitalized patients with acute severe ulcerative colitis (ASUC) often require surgery. Although the tumor necrosis factor antagonist infliximab is an effective salvage therapy to prevent colectomy in patients with ASUC, optimal dosing is unclear. Calculated infliximab clearance has been associated with important outcomes in patients with ulcerative colitis, but its utility in patients with ASUC has not been established. We assessed the relationship between calculated the baseline infliximab clearance before infliximab salvage therapy and the requirement for colectomy in patients hospitalized for ASUC. METHODS: We obtained data from hospitalized patients with ASUC who initiated infliximab therapy. We then calculated the baseline infliximab drug clearance in these patients based on an existing formula. The primary aim was to compare clearance between patients who required colectomy 6 months later and patients who did not require colectomy. Receiver operating characteristic curve analyses evaluated clearance thresholds for colectomy. Multivariable logistic regression analysis evaluated factors associated with colectomy. RESULTS: In 39 patients with ASUC, the median baseline calculated clearance was higher in patients requiring colectomy at 6 months than in patients without colectomy (0.733 vs 0.569 L/d; P = .005). An infliximab clearance threshold of 0.627 L/d identified patients who required colectomy with 80.0% sensitivity and 82.8% specificity (area under the curve, 0.80). A higher proportion of patients with infliximab clearance of 0.627 L/d or more underwent colectomy within 6 months (61.5%) than patients with lower infliximab clearance values (7.7%) (P = .001). Multivariable analysis identified baseline infliximab clearance as the only factor associated with colectomy. The infliximab dose in the hospital was higher in patients who required colectomy. Results were similar at 30 days and 1 year. CONCLUSIONS: In patients hospitalized with ASUC, higher values of calculated infliximab clearance before infliximab administration is associated with higher rates of colectomy. Although patients who required colectomies received higher doses, data on infliximab concentrations are lacking. Infliximab pharmacokinetic models are needed for patients with ASUC to allow comparative trials on clearance-based vs standard dosing.
引用
- Battat R, Hemperly A, Truong S, et al. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32348905. doi:10.1016/j.cgh.2020.03.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。